{"title": "Find a Doctor", "author": null, "url": "https://www.dana-farber.org/find-a-doctor/robert-j-soiffer/", "hostname": "dana-farber.org", "description": "Robert J. Soiffer, MD - Medical Oncology. Dr. Soiffer graduated from New York University School of Medicine in 1983, and trained in internal medicine at Brigham and Women's Hospital, where he also was chief medical resident. He joined DFCI in 1988, after completing a medical oncology fellowship. He is currently chief of the Division of Hematologic...", "sitename": "Robert J. Soiffer, MD - Dana-Farber Cancer Institute", "date": "2013-06-06", "cleaned_text": "08 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37156098) Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Adv. 2023 08 08; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37216223) Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma. Clin Cancer Res. 2023 Jul 18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37463058) Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib J Med. 2023 Jul 13; 389(2):188-190. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37437151) Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2023 Jun 15; 141(24):2932-2943. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36862975) Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem Adv. 2023 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36595453) Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid 2023 06 View response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 141(15):1817-1830. in: or posttransplant or settings. Blood. 2023 04 13; 141(15):1884-1888. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36332187) Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Cell Ther. 2023 07; 29(7):455.e1-455.e9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37015320) Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 05; 29(5):337.e1-337.e5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36736784) View in: \"harmless\" antibiotic 2022 12 08; 140(23):2420-2422. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36480222) Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023 03; 29(3):151-163. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36442770) A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35484649) Severe Acute Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: in: Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers. diagnostic genetics on remission MRD and transplantation outcomes in older patients with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35696582) Expansion, persistence, memory-like NK 05 Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release 2022 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35526780) Randomized controlled trial of geriatric consultation versus standard adults Blood 11; 6(1):181-188. View in: RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 12 28; 5(24):5536-5545. View in: 01 10; 40(2):189-201. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34793200) Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021 11 09; 37(6):109992. View View Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leuk Lymphoma. 2021 12; of CTLA-4 blockade for myeloid malignancies II with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host Bone Transplant. 2021 May; 56(5):1217. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33041331) HLA Haploidentical Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood. 2021 Apr 13. View in: Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit Apr; Myelodysplastic Syndromes-Long-Term Follow-Up of [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33775615) Acute Myeloid Leukemia Hematopoietic in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33840625) Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Transplant Cell in: COVID-19 cell transplantation and immune effector cell therapy: a US cancer center experience. 5(3):861-871. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33560397) COVID-19-induced enterade\u00ae to Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. Asian Pac Cancer Prev. 2021 Jan 01; 22(1):301-304. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33507712) Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer. 2021 03 15; 127(6):875-883. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33237587) Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from 2021 04; 35(4):1166-1175. View in: Oral Dis. 2021 09; 27(6):1451-1454. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33037754) Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32938797) Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32895491) Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32882002) Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020 09 01; 130(9):4624-4636. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32516138) Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute. 4(13):3205-3208. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32663295) Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32533060) nivolumab for malignancies [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32374880) Defibrotide formulations contain (1?3)-\u00df-D-glucan that could influence clinical diagnostic testing. Bone Marrow Transplant. 2020 10; 55(10):2045-2046. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32231251) Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. Br J Haematol. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32157682) B and disease. Blood. 2020 01 02; 135(1):28-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31697815) Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission. Blood. 2019 Nov 13; 134(Supplement_1):48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31724009) Incidence, Predictors, after Reduced-Intensity Allogeneic Hematopoietic Cell Marrow Transplant. 2020 03; 26(3):529-539. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31678537) A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31616065) Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020 03; 55(3):485-495. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31576023) Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31471324) A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Marrow Transplant. 2020 05; 26(5):835-844. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31505228) Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019 12; 25(12):2383-2387. View in: inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019 08; 54(Suppl 2):798-802. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31431704) Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Blood Marrow Transplant. 2019 11; 25(11):2143-2151. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31271885) Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019 07 25; clinical to low-dose IL-2 in patients with refractory chronic graft-versus-host 04 09; Efficacy and effects of photopheresis plus interleukin-2 in chronic graft-versus-host Blood Adv. 2019 04 09; 3(7):969-979. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30936057) Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies. J Am Geriatr Soc. 2019 for amelioration chronic Am J Transplant. 2019 06; 19(6):1820-1830. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30748099) Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation. Respir Res. 2019 Jan 21; 20(1):15. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30665420) Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Res. 2019 01; 7(1):100-112. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30396908) Blood. 2019 01 03; Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Blood Marrow Transplant. 2019 01; 25(1):137-144. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30081073) Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol 2018 11; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30006305) Cytomegalovirus Infection Among Cord Blood of Cytomegalovirus Events without Related donor transplants: has posttransplantation nullified the of disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer. 2018 10; 65(10):e27269. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29873895) Final results from study for patients with hepatic veno-occlusive disease/sinusoidal J in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29767845) Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2344-2353. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29758394) High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29724895) Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA of carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29884406) A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29555313) Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host 21; 131(25):2836-2845. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29549175) Immunohistopathological characterization and the of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study. Oral Dis. 2018 May; 24(4):580-590. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29197137) Financial Hardship after Hematopoietic Cell Lack of on Survival. Blood. 2018 Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018 05; 103(3):522-530. cell transplantation. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29296897) Outcomes after in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow with autologous targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 130(26):2889-2899. View in: Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 02; 24(2):228-241. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28939455) Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation and risk of bacteremia following allogeneic hematopoietic cell transplantation. Oral in graft-versus-host disease [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28473406) Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017 07 06; obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 07; 178(1):112-118. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28444784) Continuation Intrauterine Device During Hematopoietic Stem Cell Transplant: A and allogeneic Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biol Blood Transplant. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28151427) Safety and efficacy of allogeneic stem cell View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28068180) Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27812545) Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27989929) Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant. 2017 01; DNA After allogeneic stem cell transplantation for lymphoma. Br Haematol. 2016 175(5):841-850. View in: Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 11; 22(11):2084-2091. View Fludarabine/Melphalan Conditioning in Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biol Transplant. 2016 10; 22(10):1808-1815. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27470290) Haematopoietic cell transplantation with and sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. 2016 175(3):496-504. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27434660) Relapse Transplantation. J Med. 2016 Jul 14; 375(2):143-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27410923) The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27479034) Therapeutic regulatory T-cell established murine chronic GVHD in a manner. Blood. 2016 08 18; 128(7):1013-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27385791) A phase I study T-cell-depleted donor lymphocyte infusion for relapse after 10; 101(10):1251-1259. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27354021) Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 10; 122(19):3005-3014. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27315441) Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27153389) Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 08; 22(8):1504-1510. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27184627) Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27073224) The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27070704) The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1977-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27003236) Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016 Aug; 51(8):1121-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26999469) Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016 05 19; 127(20):2489-97. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26944544) An interactive video-based approach to diet education for patients posthematopoietic stem cell transplantation. J Clin Oncol. 2016 to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016 Mar; 91(3):322-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26701142) Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26825712) Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood 101(4):499-505. addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26729448) Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26748160) Pilot experience F1000Res. 2015; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26835003) recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26670634) Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Transplant. 2016 Jan; 22(1):80-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26260679) Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep; 100(9):1222-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26088931) A Bortezomib-Based and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1907-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26055298) Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1583-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26009261) Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25852057) The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Transplant. 2015 May; 21(5):873-80. View in: cytokines are antibody Res. 2015 Mar 01; 21(5):1010-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25538258) Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol. 2015 Feb 01; 33(4):364-9. for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant. 2015 Mar; 21(3):509-16. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25482866) Readmissions following umbilical cord blood cell transplantation. Oncol. 2014 Oct 20; 32(30_suppl):272. View in: Nov; 124(11):4867-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25271622) Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol. 2014 Dec; 89(12):1097-101. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25195500) Phase I trial of maintenance allogeneic hematopoietic stem cell transplantation for fms-like 3 internal tandem duplication acute myeloid Transplant. 2014 Dec; 20(12):2042-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25239228) Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014 Sep 02; 161(5):319-27. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25047577) Sequential infusion of infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. 2014 Dec; 89(12):1092-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25132538) Somatic mutations predict outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. 01; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25092778) A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1737-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25017765) Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1717-21. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24979731) Donor chimerism early after reduced-intensity hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24907627) Increased mitochondrial T allogeneic cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24859877) Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis Blood. 2014 Jun 19; 123(25):3988-98. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24820310) Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014 Jun 05; 123(23):3664-71. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24744269) Randomized, receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014 Jun; 20(6):858-64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24607553) White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol. 2014 Jun; 89(6):591-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24549932) Factors associated and chronic graft-versus-host disease after allogeneic hematopoietic Apr; 89(4):404-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24375545) Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24462743) BK virus disease after allogeneic stem cell transplantation: a cohort analysis. Biol Blood Marrow Transplant. 2014 Apr; 20(4):564-70. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24462984) Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/\u00df-catenin pathway and alters immune reconstitution after UCBT. Blood 2014 Jan 17; 4:e178. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24442207) Isavuconazole treatment of Microbiol. 2014 Mar; 52(3):1016-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24403304) of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb 27; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24357730) Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Marrow Transplant. 20(2):285-7. View in: View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28136438) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014 Mar; 20(3):295-308. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24141007) Outcome and prognostic factors for who relapse after allogeneic hematopoietic stem cell transplantation. Biol 2013 19(12):1713-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24076323) Prostaglandin-modulated umbilical cord blood hematopoietic 2013 Oct 24; 122(17):3074-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23996087) Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Aug 08; 369(6):517-28. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23924002) Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013 Aug 22; 122(8):1510-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23861248) Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Transplant. 2013 Sep; 19(9):1374-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23791626) Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center. J Oncol Pract. 2013 Sep; 9(5):e228-33. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23943893) Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 03; 5(179):179ra43. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23552371) Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23562738) Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013 Jun 01; 207(11):1694-702. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23460751) Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Transplant. 2013 May; 19(5):804-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23416855) KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplant. 2013 Jul; 48(7):1000-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23318536) Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23240658) Drug safety Drug Saf. 2013 Jan; 12(1):123-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23228043) Reducing unnecessary testing on admission in autologous stem cell transplant (SCT) patients. J cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S88-90. Expression of a4\u00df7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplant. 2013 Apr; 48(4):598-603. View in: hematopoietic SCT correlate with the development of chronic Transplant. 2013 Apr; 48(4):593-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23000654) Long-term follow-up transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013 Feb; 27(2):362-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22955330) Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic 2012 Sep 10; 30(26):3202-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22869883) Safety and efficacy of defibrotide treatment hepatic Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22766223) A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26; 120(4):905-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22709687) Expression of CD30 in patients with acute graft-versus-host Blood. 2012 Jul 19; 120(3):691-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22661699) Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013 Jan; 48(1):146-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22609885) Cord-blood hematopoietic stem cell transplant an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol 2012 Nov; 18(11):1638-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22564265) Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012 Jun 07; 119(23):5591-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22496153) Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012 Jun; 87(6):569-72. View in: in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22267603) To induce, or not to induce, that is the (still unanswered) question. Biol Blood Marrow Transplant. 2012 Mar; 18(3):332-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22245597) Anti-T cell antibodies as part the preparative regimen in hematopoietic cell transplantation--a debate. Biol 2012 Jan; Suppl):S111-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22226093) Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant. 2012 Jul; 18(7):989-1006. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22155504) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec bone and death. 2011 Nov 23; 3(110):110ra118. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22116933) Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012 May; 18(5):805-12. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22015993) Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011 Dec 15; 118(25):6691-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21940825) The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 18(5):708-15. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21906576) Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011 Nov 03; 118(18):5021-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21900196) Cord colitis syndrome in cord-blood transplantation. N J Med. 2011 Sep 01; 365(9):815-24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21879899) Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74. View a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21875505) Combined CD4 T-cell and antibody to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation. Blood Transplant. 2012 Apr; 18(4):575-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21839706) Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012 Feb; 18(2):280-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21810400) Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1796-803. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21699879) epithelial dysplasia carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011 Jun; 46(6):884-91. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21460866) Impact of immune modulation antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for 117(25):6963-70. View TLR-stimulating complexes J Clin Invest. 2011 121(4):1574-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21403403) Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011 tiuxetan followed allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011 Dec; 46(12):1503-9. A large fungal disease after remote inoculation in transplant recipients. Clin Infect Dis. 2011 Jan 01; 52(1):e7-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21148507) Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1196-204. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21193054) Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21159637) Allelic variations in CYP2B6 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J in: in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21097674) Seroprotective titers against A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Mar; 17(3):434-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20950701) Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20870027) Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. Jun; 17(6):852-60. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20854920) CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant. 2011 May; 17(5):682-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20713164) Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20697368) Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective Lancet Oncol. lymphocyte Cancer Res. 2010 May 15; 16(10):2729-39. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20460482) Altered regulatory T patients with CD4+ lymphopenia following allogeneic hematopoietic stem May; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20389017) disease using endothelial second hematologic malignancies Transplant. 2010 Jul; 16(7):1025-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20178854) Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20167278) Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant. 2010 Nov; 45(11):1611-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20154738) Serologic markers of effective against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 70(4):1344-55. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20124481) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20114084) Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20107229) Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Res. Feb 01; 70(3):906-15. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20103624) Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010 Jun; 16(6):792-800. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20074656) Donor-recipient mismatch for common gene polymorphisms in disease. Nat Genet. 2009 Dec; 41(12):1341-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19935662) Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant. 2010 Jun; 45(6):1062-7. validation study grouping scheme for patients with myelodysplastic syndromes. 2010 May; 45(5):877-85. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19766729) Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. Biol Blood Marrow Transplant. 2010 Jan; reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009 Oct 29; 114(18):3956-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19713456) Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell early after allogeneic stem cell transplantation. Proc Natl Acad Sci U in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19717467) Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; View prophylaxis reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009 Jul; 15(7):844-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19539216) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19509382) Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant. 15(7):777-84. View in: expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19203731) B-cell homeostasis and excess human 2009 Apr 16; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19168788) High-resolution HLA matching Transfusion. 2009 May; 49(5):995-1002. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19159415) Finding the right are antibody during immune-mediated destruction. Blood. 2009 Feb 19; 113(8):1681-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19008459) Improved survival in prophylaxis 10; 26(35):5767-74. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19001324) Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1231-8. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18940677) CTLA4 blockade relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 Feb 12; 113(7):1581-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18974373) Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008 Oct; 83(10):771-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18756547) Sirolimus is veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01; related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008 Aug; 14(8):920-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18640576) Immune modulation and chronic 2008 Aug; 42 Suppl 1:S66-S69. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18724307) Recurrent acute promyelocytic a sacral root mass. and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18342784) Individual physician practice variation in cell transplantation. Clin Oncol. 2008 2008 Feb; 14(2):197-207. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18215780) Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008 Jan; 14(1):110-5. View graft-versus-host disease: how in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18162235) Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008 Mar; 41(6):523-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18037942) A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):28-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18158958) High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17947475) 2007 Jul 10; 69(2):156-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17620548) Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007 sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007 Apr 01; 109(7):3108-14. View hematopoietic stem cell transplantation: a Blood. 2007 Jul 15; 110(2):490-500. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17392502) Impact of cytogenetics on outcome de novo and therapy-related AML and MDS after allogeneic transplantation. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17531775) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007 May 15; 109(10):4586-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17234738) Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan; 13(1):82-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17222756) Differential epitope mapping of in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and 01; 109(5):2001-7. improved progression-free survival nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17084369) Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17067911) Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006 Aug; 38(4):305-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16819438) HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 May; 37(9):845-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16532020) IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006 Sep 01; 108(5):1571-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16645171) Blood. 2005 Dec 15; 106(13):4389-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16131571) Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Transplant. 2005 11(7):551-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15983555) Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15; 106(8):2903-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15972448) Graft-versus-leukemia target are expressed on myeloid progenitor cells. Clin after non-methotrexate-containing graft-versus-host antibody responses to vaccine after autologous hematopoietic stem cell transplantation. Transplant. 11(3):213-22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15744240) Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15714125) Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant. 2005 Jan; 35(1):85-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15531904) Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005 Jan; 35(1):77-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15502851) Antibody antigens correlate with chronic graft-versus-host disease and remission. Blood. 2005 Apr 01; 105(7):2973-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15613541) Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol. 2005 Jan; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15574506) Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant. 2004 Dec; 34(11):987-94. View Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15459007) Extended follow-up leukemia relapse after allogeneic durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; Bone Marrow Transplant. 2004 Jul; 34(2):123-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15133487) Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004 May; 10(5):328-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15111932) Safety and efficacy of denileukin patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. 2004 Aug 15; 104(4):1224-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15113758) Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004 Apr Graft-versus-host of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant. 2003 Dec; 9(12):760-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14677115) Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2003 Dec; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14647268) Fatal hepatic Nov 01; 102(9):3455-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14568907) Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004 Jan 01; 103(1):353-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14512314) Vaccination with irradiated, autologous engineered to granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003 Oct 15; 102(8):2768-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12855583) Optimistic expectations and survival after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003 Jun; 9(6):389-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12813447) Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01; 102(5):1601-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12730113) Biologic activity of cytotoxic T antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci A. 2003 Apr 15; 100(8):4712-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12682289) MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3398-403. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12626761) Quantitative monitoring non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002 Oct 15; 100(8):2697-702. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12351374) CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 2002 Oct 01; 62(19):5517-5522. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12359762) Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood. 2003 Feb 01; 101(3):831-6. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12393732) A novel rapid method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003 101(1):363-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12393452) Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12393437) Interleukin-1 blockade does a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic transplantation. Blood. 2002 Nov 15; 100(10):3479-82. View View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12134098) Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res. Jul; of prophylactic infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12036895) Combination immunotherapy with rituximab and in patients with relapsed or refractory follicular non-Hodgkin's II study destruction. Proc Natl Acad Sci U S A. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11983866) A phase recombinant interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002 Mar; 29(5):373-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11919725) Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32. 2002; 8(11):601-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12463479) Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002; 8(8):444-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12234170) Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(3):139-44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11939603) The history and future depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem after allogeneic marrow transplantation in 2001 Aug 15; 98(4):1116-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11493459) T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma Blood. 2001 a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11416219) A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001 Apr 27; 71(8):1131-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11374415) CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11181681) Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):223-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11349809) stem-cell 2000 Nov; 14(11A):229-40. View in: Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 106(5):705-14. View in: Adjuvant high-dose interferon alfa-2b Cancer J. 2000 May-Jun; 6(3):139-45. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10882328) Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant. 2000 Mar; 25(6):623-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10734296) Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10607724) Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant. 2000; 6(4):375-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10917573) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999 Nov 15; 94(10):3325-33. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10552941) Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact donor lymphocyte Autologous bone after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999; 5(4):262-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10465106) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9789055) Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood. 1998 Oct 15; 92(8):2725-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9763556) Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9680339) Marrow Transplant. 1998 Jun; 21(12):1177-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9674848) Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998 May 15; 91(10):3671-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9573003) IGIV: a potential role for hepatitis B prophylaxis in the bone marrow peritransplant period. Bone Marrow Transplant. lymphoma: for long-term remission. factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood. 1997 Dec 15; 90(12):4996-5001. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9389719) Guillain-Barr\u00e9 View in: the very late antigen (VLA)/beta1 integrin stimulation is associated with impaired T-cell signaling through VLA-4 after allogeneic bone marrow transplantation. Blood. Nov View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9354695) In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Nov; 3(5):267-72. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9450922) Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin 100(4):855-66. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9259585) CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997 Apr 15; 89(8):3039-47. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9108425) CD6+ T cell depleted allogeneic marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow 3(1):11-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9209736) lymphocyte low-dose interleukin for malignant Cancer Res. 1997 Jan; 3(1):17-24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9815532) A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther. 1997 Jan 01; 8(1):111-23. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8990000) Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation. 1996 Nov 15; 62(9):1358-60. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8932286) High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 01; 88(7):2780-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8839876) Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2334-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8822956) Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2228-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8822943) R24 of alloantigen-specific T cell Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1051-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8807113) Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin Cancer Res. 1996 Mar; View associated with t(8;13)(p11;q11): description a distinctive clinicopathologic 1995 Apr 01; 85(7):1881-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7661940) Mar; Feb 15; View CD2 pathways after CD6-depleted allogeneic bone [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7849301) Immunomodulatory effects of View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8582896) Myelodysplastic syndrome as complication following autologous bone marrow transplantation for non-Hodgkin's mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994 Oct 01; 84(7):2109-14. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7919323) of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1994 Aug 01; 84(3):964-71. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8043878) Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. J Invest. in: after T cell-depleted allogeneic and autologous bone marrow transplantation. Transplantation. 1994 May 27; 57(10):1465-73. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7910987) A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood. 1994 May 01; 83(9):2707-14. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8167349) The effect of minor ABO mismatches on the incidence of graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 57(5):780. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8140649) Interleukin-12 augments lymphocytes from patients with hematologic and solid malignancies. 01; 82(9):2790-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8106018) Monoclonal antibody-purged bone marrow Blood. 1993 Oct 15; 82(8):2568-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8400304) Prediction of graft-versus-host disease analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7691252) Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant. 1993 Sep; 12(3):243-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8241984) Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993 Aug 15; 82(4):1366-76. 1993 May; 11(5):931-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8487057) Selective of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. Suppl 3:S7-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8124262) Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest. 1993 Jan; 91(1):123-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7678599) Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992 Jul; 10(7):1191-200. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1607923) Human bone depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute May 01; 79(9):2229-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1571539) Immune-mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. Medicine (Baltimore). 1992 Mar; 71(2):73-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1347635) Response of human natural cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. Mar 01; 175(3):779-88. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1346796) Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow Blood. 1992 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1730094) Hepatic dysfunction Dec; 52(6):1014-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1750063) Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant J Clin Oncol. 9(12):2110-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1960552) Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood. 1991 Nov 15; 78(10):2759-67. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1824268) Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant. 1991 Aug; 8(2):143-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1933056) Autologous bone marrow transplantation in patients with a history of low-grade B-cell non-Hodgkin's [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2039834) Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood. autologous bone 1991 Feb 15; 77(4):712-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1993214) Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2043874) Autoimmune pancytopenia following allogeneic bone Bone Marrow Transplant. 1990 Dec; 6(6):445-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1965793) Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Nov; T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood. 1990 Jul 01; 76(1):235-44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2194591) Reconstitution of T-cell function 1990 May 15; 75(10):2076-84. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1970938) Autologous non-Hodgkin's lymphoma: very low treatment-related mortality in 100 as a single "}